Welcome to the Integrated Research Application System

IRAS Project Filter

✓ England✓ Scotland

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

1. Is your project research?		
2. Select one category from the list below:		
Clinical trial of an investigational medicinal product		
Clinical investigation or other study of a medical device		
Combined trial of an investigational medicinal product and an investigational medical d	evice	
Other clinical trial to study a novel intervention or randomised clinical trial to compare in	terventions	s in clinical practice
Basic science study involving procedures with human participants		
Study administering questionnaires/interviews for quantitative analysis, or using mixed methodology Study involving qualitative methodology	quantitativ	e/qualitative
Study involving qualitative methods only		(/
 Study limited to working with human tissue samples (or other human biological sample only) 	s) and da	ta (specific project
Study limited to working with data (specific project only)		
Research tissue bank		
Research database		
If your work does not fit any of these categories, select the option below:		
Other study		
2a. Please answer the following question(s):		
a) Does the study involve the use of any ionising radiation?	O Yes	No
b) Will you be taking new human tissue samples (or other human biological samples)?	O Yes	No
c) Will you be using existing human tissue samples (or other human biological samples)?	O Yes	No

Date: 23/09/2016 1 215928/1011412/37/342

16/LO/1827
Wales Northern Ireland
3a. In which country of the UK will the lead NHS R&D office be located:
England
◯ Scotland
○ Wales
O Northern Ireland
This study does not involve the NHS
4. Which applications do you require?
IMPORTANT: If your project is taking place in the NHS and is led from England select 'IRAS Form'. If your project is led from Northern Ireland, Scotland or Wales select 'NHS/HSC Research and Development Offices' and/or relevant Research Ethics Committee applications, as appropriate.
☑ IRAS Form
Confidentiality Advisory Group (CAG)
☐ National Offender Management Service (NOMS) (Prisons & Probation)
For NHS/HSC R&D Offices in Northern Ireland, Scotland and Wales the CI must create NHS/HSC Site Specific Information forms, for each site, in addition to the study wide forms, and transfer them to the PIs or local collaborators.
For participating NHS organisations in England different arrangements apply for the provision of site specific information. Refer to IRAS Help for more information.
Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. Is your study exempt from REC review? Yes No
5. Will any research sites in this study be NHS organisations?
5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or a Diagnostic Evidence Co-operative in all study sites? Please see information button for further details.
Please see information button for further details.
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio?
Please see information button for further details.

Date: 23/09/2016 2 215928/1011412/37/342

Yes

O No

IRAS Version 5.3.2

The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies happen in the NHS e.g. by providing access to the people and facilities needed to carry out research "on the ground".

If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form (PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your study.

6. Do you plan to include any participants who are children?
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?
9. Is the study or any part of it being undertaken as an educational project?
10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?
<u> </u>
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?

Integrated Research Application System

Application Form for Research administering questionnaires/interviews for quantitative analysis or mixed methodology study

IRAS Form (project information)

Please refer to the E-Submission and Checklist tabs for instructions on submitting this application.

The Chief Investigator should complete this form. Guidance on the questions is available wherever you see this symbol displayed. We recommend reading the guidance first. The complete guidance and a glossary are available by selecting <u>Help</u>.

Please define any terms or acronyms that might not be familiar to lay reviewers of the application.

Short title and version number: (maximum 70 characters - this will be inserted as header on all forms) Perioperative Quality Improvement Programme: Patient Study

Please complete these details after you have booked the REC application for review.

REC Name:

South East Coast

REC Reference Number:Submission date:
16/LO/1827
23/09/2016

PART A: Core study information

1. ADMINISTRATIVE DETAILS

A1. Full title of the research:

Improving perioperative care through the use of quality data: Patient Study of the Perioperative Quality Improvement Programme

A3-1. Chief Investigator:

Post

Title Forename/Initials Surname
Dr Suneetha Ramani Moonesinghe

Director, UCL/UCLH Surgical Outcomes Research Centre; Consultant Anaesthetics &

Intensive Care; Honorary Senior Lecturer, UCL

Qualifications BSc (Hons) MRCP FRCA FFICM MD(Res)
Employer University College London Hospitals NHS Trust

Work Address Anaesthetics Department

Podium 3, Maple Link corridor, University College Hospital

235 Euston Road

Post Code NW12BU

Work E-mail ramani.moonesinghe@uclh.nhs.uk

* Personal E-mail rmoonesinghe@gmail.com

Work Telephone

16/LO/1827

* Personal Telephone/Mobile 07956620717

Fax

* This information is optional. It will not be placed in the public domain or disclosed to any other third party without prior

A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application.

A4. Who is the contact on behalf of the sponsor for all correspondence relating to applications for this project?

This contact will receive copies of all correspondence from REC and HRA/R&D reviewers that is sent to the Cl.

Title Forename/Initials Surname

Ms Suzanne **Emerton**

Address Joint Research Office.

1st floor Maple House, 149 Tottenham Court Road

London

Post Code W1T 7DB

E-mail randd@uclh.nhs.uk Telephone 02034472198

Fax

A5-1. Research reference numbers. Please give any relevant references for your study:

Applicant's/organisation's own reference number, e.g. R & D (if

available):

Sponsor's/protocol number: 16/0577 Protocol Version: 1.4

Protocol Date: 21/09/2016

Funder's reference number:

Proiect website:

www.niaa-hsrc.org.uk/PQIP

Additional reference number(s):

Ref.Number Description

Reference Number

Registration of research studies is encouraged wherever possible. You may be able to register your study through your NHS organisation or a register run by a medical research charity, or publish your protocol through an open access publisher. If you have registered your study please give details in the "Additional reference number(s)" section.

A5-2. Is this application linked to a previous study or another current application?

Yes

O No

Please give brief details and reference numbers.

PQIP Database (IRAS number 211179) - this application received a favourable REC opinion on 12th August 2016

2. OVERVIEW OF THE RESEARCH

To provide all the information required by review bodies and research information systems, we ask a number of specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and members of the public. Please read the guidance notes for advice on this section.

Date: 23/09/2016 5 215928/1011412/37/342 **A6-1. Summary of the study.** Please provide a brief summary of the research (maximum 300 words) using language easily understood by lay reviewers and members of the public. Where the research is reviewed by a REC within the UK Health Departments' Research Ethics Service, this summary will be published on the Health Research Authority (HRA) website following the ethical review. Please refer to the question specific guidance for this question.

This application is to gather and analyse patient data using the PQIP Database.

PQIP will measure complications after major planned surgery and seek to improve these outcomes through feedback of data to clinicians. A REC/CAG application for the PQIP Database has already received a favourable opinion. This analysis will answer important research questions about variation in quality of care in major surgery.

We expect that this substantial collaborative work will lead to valuable insights regarding the ways in which hospitals use data to drive improvements in care.

A6-2. Summary of main issues. Please summarise the main ethical, legal, or management issues arising from your study and say how you have addressed them.

Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that can be identified and managed routinely. Others may present significant issues requiring further consideration by a REC, HRA, or other review body (as appropriate to the issue). Studies that present a minimal risk to participants may raise complex organisational or legal issues. You should try to consider all the types of issues that the different reviewers may need to consider.

This is an observational study and we do not see major ethical or other issues.

We will seek patient consent for participation. A Participant Information Sheet will be provided which will explain the reasons for data collection and give an overview of the data which will be collected and stored. Data will be stored in the PQIP Database which has already received a favourable REC/CAG opinion.

We anticipate a large number of hospitals participating, at least 70 in the first year, and we hope that this number will rise in years to come. This may pose some organisational challenges but both the Chief Investigator, and the organisation supporting this study (the National Institute for Academic Anaesthesia's Health Services Research Centre based at the Royal College of Anaesthetists) have experience in running major multi-centre studies involving up to 200 Trusts, therefore we are confident that we have the administrative and organizational capacity to manage the study.

3. PURPOSE AND DESIGN OF THE RESEARCH

A7. Select the appropriate methodology description for this research. Please tick all that apply:			
Case series/ case note review			
Case control			
Cohort observation			
Controlled trial without randomisation			
Cross-sectional study			
☑ Epidemiology			
☐ Feasibility/ pilot study			
Laboratory study			
☐ Metanalysis			
Qualitative research			
Questionnaire, interview or observation study			
Randomised controlled trial			
Other (please specify)			

A10. What is the principal research question/objective? Please put this in language comprehensible to a lay person.

What is the rate of postoperative complications after major inpatient surgery in the UK; how does it vary between hospitals and how is this information used to improve patient outcome?

A11. What are the secondary research questions/objectives if applicable? Please put this in language comprehensible to a lay person.

RQ1. What is the failure to rescue rate in the NHS and how does it vary between hospitals?

RQ2. What is the relationship between short-term complications and longer-term Health Related Quality of Life (HRQOL), and can longer-term HRQOL be improved through reducing postoperative complications?

RQ3. Can the quality of care be improved through the feedback of data to clinicians and managers, leading to improvements in complications and failure to rescue?

A12. What is the scientific justification for the research? Please put this in language comprehensible to a lay person.

There is currently no national or comprehensive database which records postoperative complications on patients in the UK outside a few specific surgical complications (e.g. return to operating room) or procedures (e.g. nephrectomy). This is an important omission as significant postoperative complications are up to 10 times more common than short-term mortality after surgery, and have been independently associated with reduced postoperative survival and quality of life. We currently have no way of measuring and therefore improving upon these important outcomes. We also know from the US, that there is wide variation in "failure to rescue" between different healthcare institutions - i.e. if a patient develops a postoperative complication, whether they die or not after this complication varies up to 15-fold between different healthcare providers. We do not have access to this type of information in the UK presently, and this study will provide these data.

PQIP will measure both objective outcomes (morbidity and mortality) and also outcome from the patient perspective after major surgery. The web-based data entry system will include the features which have been suggested by stakeholders to be important for facilitating the use of data for improvement, such as near-real time feedback, feedback provided in easily understandable and graphical formats, and explanations for statistical analyses and risk-adjustment techniques.

A13. Please summarise your design and methodology. It should be clear exactly what will happen to the research participant, how many times and in what order. Please complete this section in language comprehensible to the lay person. Do not simply reproduce or refer to the protocol. Further guidance is available in the guidance notes.

Data will be collected on a sample of patients undergoing major surgery (defined prospectively) in participating hospitals.

Sampling strategy:

All NHS hospitals in the UK will be invited to participate. So far we have interest from approximately 70 hospitals. Only patients undergoing surgery defined by our list of eligible procedures (see Appendix) will be eligible for inclusion. Each hospital will recruit a maximum 5 patients per week. The patients to be approached for consent will be based on a random sampling strategy which will involve an 8-day rolling sampling cycle (i.e. the first 5 patients starting from Monday morning in week one, followed by the first 5 patients starting from Tuesday in week two etc etc). If any of the first 5 patients approached refuse consent, then consecutive patients will be approached for consent until the target recruitment number has been achieved.

Data collection:

Each consenting patient will complete baseline questionnaires before their surgery, and again 1 day, 3 days, 6 months and 12 months after their surgery. Objective risk, process and outcome data will be collected on patients during their inpatient stay. Hospital data will be linked with Hospital Episode Statistics (HES) and Office of National Statistics (ONS) mortality data at patient identifiable level. This is necessary to track adverse outcomes which occur after discharge from hospital (e.g. readmission within 30 days of surgery - from HES data; longer term mortality - from ONS)

Dataset:

All data collected are evidence based and where appropriate, formally validated.

These include:

- Patient risk factors for the purposes of risk adjustment (the components of risk adjustment systems identified in a published systematic review as being accurate)
- Patient morbidity data using the validated Post-Operative Morbidity Survey (POMS) on Day 7 post-op and the Clavien Dindo surgical complications grading system on discharge from hospital

Date: 23/09/2016 7 215928/1011412/37/342

- Patient reported outcome data - the EQ5D is a validated measure of health-related quality of life; the Quality of Recovery - 15 score is a validated measure of recovery from surgery; the Bauer patient satisfaction measure is a validated measure of postoperative discomfort and satisfaction with anaesthesia care; the WHO Disability Assessment Schedule 2.0 has been validated for use in patients undergoing major surgery.

Analysis plan:

Our primary outcome is POMS-defined morbidity on day 7. Our primary analysis will measure risk-adjusted variation between providers (comparing observed: expected ratios) in morbidity, mortality and failure to rescue rates, following standard methodology for ascertaining FTR rates described by Dimick. Secondary outcomes will include mortality at 90 days, disability-free survival at one year; patient reported outcome (change in health-related quality of life; time to full recovery. Analyses will include hierarchical regression modelling to determine the relationship between structure, process and outcome.

A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service users and/or their carers, or members of the public?
✓ Design of the research
Management of the research
✓ Undertaking the research
Analysis of results
☑ Dissemination of findings
None of the above
Give details of involvement, or if none please justify the absence of involvement. We will address areas prioritised by 4 James Lind Alliance Priority Setting Partnerships (JLA-PSPs): anaesthesia/perioperative care, intensive care, dementia & pressure ulcers.
We received detailed structured feedback on our protocol from members of the PCPIE group at the National Institute for Academic Anaesthesia's Health Services Research Centre (NIAA-HSRC).
Our Clinical Reference Group has two lay members. Ms Elspeth Evans is a member of the RCoA lay committee and has provided feedback on this project proposal throughout development. Ms Siobhan Atherly volunteered to be a patient voice through the Royal College of Surgeons; she is currently in follow-up from surgery & is actively involved with her local Trust Board.

4. RISKS AND ETHICAL ISSUES

RESEARCH PARTICIPANTS

A15. What is the sample group or cohort to be studied in this research?					
Select all that apply:					
Blood					
Cancer					
Cardiovascular					
Congenital Disorders					
Dementias and Neurodegenerative Diseases					
Diabetes					
Ear Ear					
Eye					
☑ Generic Health Relevance					
☐ Infection					

Date: 23/09/2016 8 215928/1011412/37/342

Inflammatory and Immune System	
☐ Injuries and Accidents	
Mental Health	
Metabolic and Endocrine	
Musculoskeletal	
Neurological	
Oral and Gastrointestinal	
Paediatrics	
Renal and Urogenital	
Reproductive Health and Childbirth	
Respiratory	
Skin	
Stroke	
Gender:	Male and female participants
Lower age limit: 18	Years
Upper age limit:	No upper age limit

A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters).

- 1. Adult patients aged 18 or older
- 2. Undergoing an elective major surgical procedure (see Appendix 5 for list of included procedures)
- 3. Has capacity to give consent to participate in this study

A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters).

- 1. Aged less than 18years
- 2. Does not have capacity, or refuses, to give consent to participate in this study

RESEARCH PROCEDURES, RISKS AND BENEFITS

A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of the research protocol. These include seeking consent, interviews, non-clinical observations and use of questionnaires.

Please complete the columns for each intervention/procedure as follows:

- 1. Total number of interventions/procedures to be received by each participant as part of the research protocol.
- 2. If this intervention/procedure would be routinely given to participants as part of their care outside the research, how many of the total would be routine?
- 3. Average time taken per intervention/procedure (minutes, hours or days)
- 4. Details of who will conduct the intervention/procedure, and where it will take place.

Intervention or procedure	1	2	3	4
Participant consent	1	0	10minutes	Conducted by Clinical Research Nurse in pre-operative assessment clinic or on morning of surgery
Patient-Reported Outcomes (PROMs) questionnaire	5	0	10	Pre-operative questions on morning of surgery; post-operative questions on days 1 and 3 after surgery as an inpatient, and then by telephone/email follow-up (dictated by patient preference) at 6 and 12 months after surgery.

A21. How long do you expect each participant to be in the study in total?	
16/LU/1827	

A22. What are the potential risks and burdens for research participants and how will you minimise them?

For all studies, describe any potential adverse effects, pain, discomfort, distress, intrusion, inconvenience or changes to lifestyle. Only describe risks or burdens that could occur as a result of participation in the research. Say what steps would be taken to minimise risks and burdens as far as possible.

The main risk to patients will be the confidentiality of their identifiable information. The processes governing data security and governance have been already granted REC/CAG approval in the linked application ('PQIP Database' - IRAS reference 211179).

Patients will experience a minor burden completing a consent form and questionnaires.

A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, embarrassing or upsetting, or is it possible that criminal or other disclosures requiring action could occur during the study?

()	Yes

12 months

No

A24. What is the potential for benefit to research participants?

At an individual patient level, there is unlikely to be a specific benefit, apart from that of being a participant in a clinical study and therefore the potential for a greater degree of surveillance for postoperative problems (through involvement of researchers in monitoring postoperative outcomes while in hospital). However, over time we hope that patients recruited into the study later in its duration might benefit through improvement in quality of care conferred through their hospital's participation in PQIP.

A26. What are the potential risks for the researchers themselves? (if any)

None

RECRUITMENT AND INFORMED CONSENT

In this section we ask you to describe the recruitment procedures for the study. Please give separate details for different study groups where appropriate.

A27-1. How will potential participants, records or samples be identified? Who will carry this out and what resources will be used? For example, identification may involve a disease register, computerised search of GP records, or review of medical records. Indicate whether this will be done by the direct healthcare team or by researchers acting under arrangements with the responsible care organisation(s).

Clinicians in participating hospitals will identify patients for entry to the database. 5 patients per week undergoing any of a predefined list of eligible surgical procedures in each hospital will be recruited.

A random sampling technique for patient identification will be used, based on an 8-day rolling rota: e.g. the first 5 patients admitted on Monday for qualifying surgical procedures in week 1, followed by the first 5 patients on Tuesday in week 2, the first 5 patients on Wednesday in week 3, etc. The sampling strategy will be communicated by the central database team at the Royal College of Anaesthetists to local sites, and local principle investigators (PIs) will be responsible for ensuring that the patients recruited adhere to the strategy. Weekly updates will be sent out by email to local PIs reminding them of which patients are to be approached. If a patient refuses consent, the next sequential patient will be approached until 5 patients are recruited.

A27-2. Will the identification of potential participants involve reviewing or screening the identifiable personal information of patients, service users or any other person?

Date: 23/09/2016 10 215928/1011412/37/342

16/LO/1827				
Yes No				
Please give details below: Patients will be identified, according to the sampling strategy described above, by clinicians in the course of routine healthcare provision or by local clinical research nurses.				
A27-3. Describe what measures will be taken to ensure there is no breach of any duty of confidentiality owed to patients, service users or any other person in the process of identifying potential participants. Indicate what steps have been or will be taken to inform patients and service users of the potential use of their records for this purpose. Describe the arrangements to ensure that the wishes of patients and service users regarding access to their records are respected. Please consult the guidance notes on this topic.				
Patients will be identified by clinicians in the course of routine healthcare provision or by local research nurses who will be bound by the principles of GCP				
A27-4. Will researchers or individuals other than the direct care team have access to identifiable personal information of any potential participants?				
A27-5. Has prior consent been obtained or will it be obtained for access to identifiable personal information?				
If Yes, please give details below.				
Consent will be sought prospectively from all patients whose data are included in the database.				
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites?				
If Yes, please give details of how and where publicity will be conducted, and enclose copy of all advertising material (with version numbers and dates).				
Posters will be displayed in preoperative assessment clinics and surgical admission wards, giving patients brief details of the study (see appendix). If they attend preoperative assessment clinic, they will be offered a Patient Information Sheet (PIS, see appendix) at that time. Otherwise, they will be provided with a PIS on arrival in hospital for their surgery.				
A29. How and by whom will potential participants first be approached?				

Patients will be approached by clinicians or by local research nurses either at preoperative clinic or on admission to hospital for their surgery.

A30-1. Will you obtain informed consent from or on behalf of research participants?

If you will be obtaining consent from adult participants, please give details of who will take consent and how it will be done, with details of any steps to provide information (a written information sheet, videos, or interactive material). Arrangements for adults unable to consent for themselves should be described separately in Part B Section 6, and for children in Part B Section 7.

If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is voluntary and fully informed.

Consent will be sought by clinicians or local research nurses. Potential participants will be provided with patient information sheets and consent forms for completion; these will provide contact details for further information including links to videos on the database website.

Date: 23/09/2016 11 215928/1011412/37/342

If you are not obtaining consent, please explain why not.

Please enclose a copy of the information sheet(s) and consent form(s).

A30-2. Will you record informed consent (or advice from consultees) in writing?						
Yes	○ No					

A31. How long will you allow potential participants to decide whether or not to take part?

This will be determined by local circumstances but will be a minimum of one hour. Posters will be displayed in preoperative assessment clinics and surgical admission wards, giving patients brief details of the study (see appendix). If they attend preoperative assessment clinic, they will be offered a Patient Information Sheet (PIS, see appendix) at that time. Otherwise, they will be provided with a PIS on arrival in hospital for their surgery. Consent will be taken prior to surgery and preoperative questionnaires completed at the time of consent. This methodology is similar to that used in the NHS Patient Reported Outcome Measures (PROMs) programme:

"....this [offering a patient a questionnaire for completion] should happen in the interval between the patient being passed fit for surgery and the treatment taking place, however, there is local discretion as to when precisely it is administered before the procedure. Completion of the pre-operative PROMs questionnaire is voluntary for the patient and their consent to participate must be granted for the data to be processed and used....."

A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or written information given in English, or who have special communication needs?(e.g. translation, use of interpreters)

Language constraint will be an exclusion criterion.

participants about this when seeking their consent initially.

A33-2. What arrangements will you make to comply with the principles of the Welsh Language Act in the provision of information to participants in Wales?

Information sheets, consent forms and questionnaires will be translated into Welsh.

A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during th study? Tick one option only.
The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which is not identifiable to the research team may be retained.
The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would
be retained and used in the study. No further data or tissue would be collected or any other research procedures carried out on or in relation to the participant.
The participant would continue to be included in the study.
Not applicable – informed consent will not be sought from any participants in this research.
Not applicable – it is not practicable for the research team to monitor capacity and continued capacity will be assumed.
Further details:
This approach is reflected in the consent form.

CONFIDENTIALITY

Date: 23/09/2016 12 215928/1011412/37/342

If you plan to retain and make further use of identifiable data/tissue following loss of capacity, you should inform

In this section, personal data means any data relating to a participant who could potentially be identified. It includes pseudonymised data capable of being linked to a participant through a unique code number.

Storage and use of personal data during the study
A36. Will you be undertaking any of the following activities at any stage (including in the identification of potential participants)?(Tick as appropriate)
Access to medical records by those outside the direct healthcare team
Access to social care records by those outside the direct social care team
☑ Electronic transfer by magnetic or optical media, email or computer networks
☑ Sharing of personal data with other organisations
Export of personal data outside the EEA
☑ Use of personal addresses, postcodes, faxes, emails or telephone numbers
Publication of data that might allow identification of individuals
Use of audio/visual recording devices
☑ Storage of personal data on any of the following:
Manual files (includes paper or film)
NHS computers
Social Care Service computers
☐ Home or other personal computers
University computers
Private company computers
Laptop computers
Further details:

A37. Please describe the physical security arrangements for storage of personal data during the study?

Patient level data will be entered by local reporters directly onto electronic CRFs via the PQIP Database (IRAS form 211179 which already received a favourable REC opinion). The database will be hosted on a server managed by UK Fast on behalf of the Royal College of Anaesthetists (RCoA).

A38. How will you ensure the confidentiality of personal data? Please provide a general statement of the policy and procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of data.

All study team members with access to confidential and/or identifiable data will be bound by the Data Protection Act, the NHS Information Governance framework and local information governance regulations. Staff within the NHS will follow the NHS Code of Confidentiality.

Among the patient identifiers, only sex will used for analysis. An anonymised dataset will be used by the central PQIP study team for analysis. In this dataset:

- the NHS number will be replaced by a unique study patient identifier
- · Date of Birth will be converted to Age on date of surgery, and trimmed to month and year of birth
- Postcode will be converted to PCT, SHA of residence, and the Office for National Statistics Lower Super Output Area, which allows the allocation of the Index of Multiple Deprivation.

A40. Who will have access to participants' personal data during the study? Where access is by individuals outside the direct care team, please justify and say whether consent will be sought.

Access to personal data within PQIP are described in the PQIP research database application 211179 and associated

protocol. For completeness:

- Consent will be sought
- Data will be anonymised for linkage as detailed above
- Only members of the research team who have fulfilled GCP training will be able to access participant data

Storage and use of data after the end of the study

A41. Where will the data generated by the study be analysed and by whom?

Anonymised data will be analysed at the following centres:

Royal College of Anaesthetists

University College London Hospitals NHS Foundation Trust

University College London Department of Applied Health Research

Analyses will be conducted by members of the study team:

Dr SR Moonesinghe (CI)

Research fellows appointed to work on the study - all clinical doctors who will have completed GCP training and who will be bound by NHS and DPA guidance on data confidentiality.

Study statistician.

A42. Who will have control of and act as the custodian for the data generated by the study?

Title Forename/Initials Surname
Mrs Sharon Drake

Post Director of Clinical Quality and Research and Deputy Chief Executive, Royal College of Qualifications BA (Hons) Classics and English, CTEFL, Postgraduate Diploma in Management Studies

Work Address Royal College of Anaesthetists

Churchill House

35 Red Lion Square, London

Post Code WC1R 4SG

Work Email sdrake@rcoa.ac.uk
Work Telephone 02070921671
Fax 02070921730

	A43. How long will	personal data be stored	l or accessed after the stu	udv has ended?
--	--------------------	-------------------------	-----------------------------	----------------

\bigcirc I	Less	than	3	months	
--------------	------	------	---	--------	--

3 − 6 months

○ 6 - 12 months

12 months – 3 years

Over 3 years

If longer than 12 months, please justify:

The PQIP database will be tracking long-term survival (up to 20 years post-enrolment)

A44. For how long will you store research data generated by the study?

Years: 30 Months:

IRAS Form Reference: IRAS Version 5.3.2

16/LO/1827

A45. Please give details of the long term arrangements for storage of research data after the study has ended. Say where data will be stored, who will have access and the arrangements to ensure security. The data will be stored on servers hosted by UK Fast who have unassuming facilities, unmarked and inauspicious with 24/7/365 on site security. UKFast have to comply with ISO 27001 standards to retain certification. ISO 27001 specifically requires that the organisation examines its information security risks, taking account of the threats, vulnerabilities, and impacts.

INICENE	EN /EC A	NID DAY	MENTS
	MESA		

	esearch participants receive any payments, reimbursement of expenses or any other benefits or incentives part in this research?
O Yes	No No
	dividual researchers receive any personal payment over and above normal salary, or any other benefits or for taking part in this research?
O Yes	No No
financial, s	the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g. hare holding, personal relationship etc.) in the organisations sponsoring or funding the research that may a possible conflict of interest?
O Yes	No No

NOTIFICATION OF OTHER PROFESSIONALS

A49-1. Will you inform the participants' General Practitioners (and/or any other health or care professional responsible for their care) that they are taking part in the study?

Yes

No

If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.

PUBLICATION AND DISSEMINATION

A50. Will the research be registered on a public database?

Yes

O No

Please give details, or justify if not registering the research.

We will register the study on clinicaltrials.gov and publish our protocol after ethics approval received

Registration of research studies is encouraged wherever possible.

You may be able to register your study through your NHS organisation or a register run by a medical research charity, or publish your protocol through an open access publisher. If you are aware of a suitable register or other method of publication, please give details. If not, you may indicate that no suitable register exists. Please ensure that you have entered registry reference number(s) in question A5-1.

Reference: 16/LO/1827

A51. How do you intend to report and disseminate the results of the study? Tick as appropriate:
✓ Peer reviewed scientific journals
Internal report
Publication on website
☐ Other publication
Submission to regulatory authorities
— Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee
on behalf of all investigators
No plans to report or disseminate the results
Other (please specify)
A52. If you will be using identifiable personal data, how will you ensure that anonymity will be maintained when publishing the results?
We will not be publishing dis-aggregated patient level data.
A53. Will you inform participants of the results?
Please give details of how you will inform participants or justify if not doing so. All participants will be given an information leaflet prior to consent. This will include details of the study website; all reports / results will be published on there and therefore participants will be able to access if they wish.
5. Scientific and Statistical Review
5. Scientific and Statistical Review A54. How has the scientific quality of the research been assessed? Tick as appropriate:
A54. How has the scientific quality of the research been assessed? Tick as appropriate:
A54. How has the scientific quality of the research been assessed? Tick as appropriate: ☑ Independent external review
A54. How has the scientific quality of the research been assessed? Tick as appropriate: ☑ Independent external review ☐ Review within a company
A54. How has the scientific quality of the research been assessed? Tick as appropriate: ☑ Independent external review ☐ Review within a company ☑ Review within a multi-centre research group
A54. How has the scientific quality of the research been assessed? Tick as appropriate: ☑ Independent external review ☐ Review within a company ☑ Review within a multi-centre research group ☑ Review within the Chief Investigator's institution or host organisation
A54. How has the scientific quality of the research been assessed? Tick as appropriate: ☑ Independent external review ☐ Review within a company ☑ Review within a multi-centre research group ☑ Review within the Chief Investigator's institution or host organisation ☑ Review within the research team
A54. How has the scientific quality of the research been assessed? Tick as appropriate: ☑ Independent external review ☐ Review within a company ☑ Review within a multi-centre research group ☑ Review within the Chief Investigator's institution or host organisation ☑ Review within the research team ☐ Review by educational supervisor
A54. How has the scientific quality of the research been assessed? Tick as appropriate: □ Independent external review □ Review within a company □ Review within a multi-centre research group □ Review within the Chief Investigator's institution or host organisation □ Review within the research team □ Review by educational supervisor □ Other Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher, give details of the body which has undertaken the review: The original protocol was peer reviewed on behalf of the Health Foundation who have provided grant funding. Since then we have refined the protocol and reviewed extensively over the past 8 months at monthly project team meetings
A54. How has the scientific quality of the research been assessed? Tick as appropriate: Independent external review Review within a company Review within a multi-centre research group Review within the Chief Investigator's institution or host organisation Review within the research team Review by educational supervisor Other Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher, give details of the body which has undertaken the review: The original protocol was peer reviewed on behalf of the Health Foundation who have provided grant funding. Since then we have refined the protocol and reviewed extensively over the past 8 months at monthly project team meetings and with input from a multi-disciplinary clinical reference group (listed at end of protocol). For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports,
A54. How has the scientific quality of the research been assessed? Tick as appropriate: Independent external review Review within a company Review within a multi-centre research group Review within the Chief Investigator's institution or host organisation Review within the research team Review by educational supervisor Other Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher, give details of the body which has undertaken the review: The original protocol was peer reviewed on behalf of the Health Foundation who have provided grant funding. Since then we have refined the protocol and reviewed extensively over the past 8 months at monthly project team meetings and with input from a multi-disciplinary clinical reference group (listed at end of protocol). For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports, together with any related correspondence. For non-doctoral student research, please enclose a copy of the assessment from your educational supervisor/ institution.
A54. How has the scientific quality of the research been assessed? Tick as appropriate: Independent external review Review within a company Review within a multi-centre research group Review within the Chief Investigator's institution or host organisation Review within the research team Review by educational supervisor Other Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher, give details of the body which has undertaken the review: The original protocol was peer reviewed on behalf of the Health Foundation who have provided grant funding. Since then we have refined the protocol and reviewed extensively over the past 8 months at monthly project team meetings and with input from a multi-disciplinary clinical reference group (listed at end of protocol). For all studies except non-doctoral student research, please enclose a copy of any available scientific critique reports, together with any related correspondence.

Date: 23/09/2016 215928/1011412/37/342 16

Other review by independent statistician						
Review by com	Review by company statistician					
Review by a st	atistician within the Chief Investigator's institution					
Review by a st	atistician within the research team or multi-centre group					
Review by edu	cational supervisor					
Other review by	y individual with relevant statistical expertise					
No review nece required	essary as only frequencies and associations will be assessed – details of statistical input not					
•	give details below of the individual responsible for reviewing the statistical aspects. If advice has onfidence, give details of the department and institution concerned.					
	Title Forename/Initials Surname Dr Mizan Khondoker					
Department	Department of Applied Health Research					
Institution	University College London					
Work Address	1-19 Torrington Place, London					
Post Code	WC1E 7HB					
Telephone	02031083952					
Fax						
Mobile						
E-mail	m.khondoker@ucl.ac.uk					

A57. What is the primary outcome measure for the study?

Postoperative Morbidity (defined using the Post Operative Morbidity Survey or POMS) on day 7

A58. What are the secondary outcome measures?(if any)

Structural measures of engagement with PQIP:

Frequency of reports being presented at clinical and managerial meetings

Please enclose a copy of any available comments or reports from a statistician.

Process measures of engagement with PQIP:

Case-ascertainment rates

Data completion

Process measures related to patient care:

Changes in compliance with process measures

Short-term patient outcome measures:

Clavien-Dindo classification of complications on discharge from hospital.

Resource utilisation:

Critical Care admission (planned)

Critical Care admission (unplanned)

Critical Care Length of Stay

Hospital length of stay

Hospital readmission within 30 days of index procedure

Longer-term patient outcome measures:

EQ5D (5L) at 6 months and one year post-surgery

World Health Organisation Disability Assessment Schedule 2.0 [26] at 6months and one year post-surgery

A59. What is the sample size for the research? How many participants/samples/data records do you plan to study in total? If there is more than one group, please give further details below.

Total UK sample size: 70000
Total international sample size (including UK): 70000
Total in European Economic Area: 70000

Further details:

Based on the number of hospitals which have indicated they want to participate, and our target recruitment rate within these hospitals, we estimate that 70,000 patients will be recruited over 4 years, (median of 5 patients per week, 50 weeks per year, in 70 hospitals).

Our aim will be to expand the study to as many UK hospitals as want to participate - therefore the sample size may exceed our target; however, our end point will be dictated by the number of years of the study (as we wish to study how patient outcomes change over time to assess the impact of the data collection and feedback on outcome) - the planned study (recruitment) duration is 4 years.

A60. How was the sample size decided upon? If a formal sample size calculation was used, indicate how this was done, giving sufficient information to justify and reproduce the calculation.

The sample size calculation has been based on previous data from studies in the US

A61. Will participants be allocated to groups at random?

Yes

No

A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by which the data will be evaluated to meet the study objectives.

Descriptive statistics will be used to describe basic demographics of participants. Risk-adjustment will be based on backward stepwise logistic regression, including multiple patient-level and operation-level variables such as age, sex, operation type and known validated risk prediction scores and their constituent variables such as the Portsmouth Physiological and operative score for the enumeration of morbidity and mortality (P-POSSUM) and the Surgical Outcome Risk Tool (SORT). Risk-adjusted morbidity and mortality will be compared between hospitals using funnel plots. Variable life-adjusted displays will be used to feedback outcome data to clinicians in near-real time. Hierarchical regression modelling will be used to analyse the relative contributions of patient and hospital factors on patient outcomes.

6. MANAGEMENT OF THE RESEARCH

A63. Other key investigators/collaborators. Please include all grant co-applicants, protocol co-authors and other key members of the Chief Investigator's team, including non-doctoral student researchers.

Title Forename/Initials Surname
Prof Mike Grocott

Post Professor of Anaesthesia and Critical Care

Qualifications MD

Employer University of Southampton

Work Address Faculty of Medicine, University of Southampton

Building 85, Life Sciences Building Highfield Campus, Southampton

Post Code SO171BJ Telephone 02381208449

Fax Mobile Work Email mike.grocott@soton.ac.uk

Title Forename/Initials Surname Dr Jonathon Wilson

Post Consultant Anaesthetist

Qualifications FRCA

Employer York Teaching Hospital Foundation Trust Work Address Anaesthetics Department, York Hospital

Wigginton Road

York

Post Code YO318HE Telephone 01904725398

Fax Mobile

Work Email jonathon.rjt.wilson@york.nhs.uk

Title Forename/Initials Surname Dr David Gilhooly

Post Research Associate

Qualifications FFCAI

Employer The London Clinic
Work Address 20 Devonshire Place

London

Post Code WCG6BW Telephone 02079354444

Fax Mobile

Work Email d.gilhooly@excite.com

Title Forename/Initials Surname Dr Maria Chazapis

Post Research Associate

Qualifications FRCA

Employer University College London Hospitals NHS Foundation Trust

Work Address Anaesthetics Department

Podium 3, Maple Link corridor, University College Hospital

235 Euston Road

Post Code NW12BU
Telephone 02034567890

Fax Mobile

Work Email m.chazapis@yahoo.com

Title Forename/Initials Surname Dr Duncan Wagstaff

Post Research Associate

Qualifications FRCA

Employer University College London

Work Address Department of Applied Health Research

1-19 Torrington Place

London

Post Code WC1E 7HB

Telephone

Fax

Mobile 07812125650

Work Email duncan_wagstaff@yahoo.co.uk

A64. Details of research sponsor(s)

Lead Sponsor			
Status: NHS	or HSC care organisation	Commercial status:	Non-
Acade	emic		Commercial
O Pharr	naceutical industry		
O Medic	cal device industry		
O Local	Authority		
Other Other	•		
If Other, p	lease specify:		
	ation University College London		
Given name	Tabitha		
Family name	Kavoi		
Address	Joint Research Office, UCL, Gower St		
Town/city Post code	London W1G8PH		
Country	UNITED KINGDOM		
Telephone	02034475274		
Fax			
E-mail			

A65. Has external	funding for the research been secured?
Funding secur	red from one or more funders
	ng application to one or more funders in progress
	n for external funding will be made
	To external funding will be made
What type of rese	arch project is this?
Standalone p	roject
Project that is	s part of a programme grant
Project that is	part of a Centre grant
Project that is	s part of a fellowship/ personal award/ research training award
Other	
Other – please sta	ate:
Please give details	s of funding applications.
Organisation	The Health Foundation
Address	90 Long Acre
	London
Post Code	WC2E 9RA
Telephone	02072578000
Fax	
Mobile	
Email	daniela.d'alessio@health.org.uk
Funding Applicat	tion Status: Secured In progress
Amount: 3	74,709
Butter	
Duration Years: 3	
Months:	
	ase specify the programme/ funding stream:
	ing stream/ programme for this research project?
	ience Fellowship
·	
Organisation	Royal College of Anaesthetists
Address	Churchill House
	35 Red Lion Square
	London
Post Code	WC1R 4SG
Telephone Fax	02070921500
Mobile	

Email

sdrake@rcoa.ac.uk

	16/LO/1827		
Funding Applica	ation Status: Secured In progress		
Amount:	71,892		
Duration			
Years:			
Months:			
If applicable, ple	ease specify the programme/ funding stream:		
What is the fund	ding stream/ programme for this research project?		
Health Services	Research Centre - statistician salary		
Organisation	Royal College of Anaesthetists		
Address	Churchill House		
	35 Red Lion Square		
Post Code	London WC1R 4SG		
Telephone	02070921500		
Fax	020, 002,000		
Mobile			
Email	sdrake@rcoa.ac.uk		
Funding Applica	ation Status: Secured In progress		
Amount: 2	260,000		
Duration			
Duration Years:	5		
Months:	-		
If applicable, please specify the programme/ funding stream:			
What is the fund PQIP	ding stream/ programme for this research project?		

A66. Has responsibility for any specific research activities or procedures been delegated to a subcontractor (other than a co-sponsor listed in A64-1)? Please give details of subcontractors if applicable.

Yes

No

A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or another country?

Yes

No

Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question A6-2 how the reasons for the unfavourable opinion have been addressed in this application.

A68-1. Give details of the lead NHS R&D contact for this research:

Title Forename/Initials Surname
Ms Suzanne Emerton

IIVAO I OIIII		16/LO/1827	IIVAO VEISIOII 3.0
Organisation	University College London Hospita	als NHS Foundation Trust	
Address	Joint Research Office, UCL		
	Gower Street		
De de Octo	London		
Post Code	WC1E6BT		
Work Email Telephone	rand.d@uclh.nhs.uk 02034475274		
Fax	02034473274		
Mobile			
Details can be ol	tained from the NHS R&D Forum we	bsite: http://www.rdforum.nhs.uk	
A68-2. Select Loc	al Clinical Research Network for NH	S Organisation identified in A6	8-1:
North Thames			
For more informa	tion, please refer to the question spec	cific guidance.	
A69-1. How long	do you expect the study to last in the	UK?	
Planned start da	te: 07/11/2016		
Planned end dat	e: 06/11/2020		
Total duration:			
Years: 4 Month	s: 0 Days: 0		
A71-1. Is this stud	ly?		
Single centre			
Multicentre			
A71-2. Where wil	the research take place? (Tick as a	appropriate)	
✓ England			
Scotland			
✓ Wales			
✓ Northern Ire	land		
_	ies in European Economic Area		
Total UK sites in	study 70		
	volve countries outside the EU?		
◯ Yes 🌘 N)		

A72. Which organisations in the UK will host the research? Please indicate the type of organisation by ticking the box and give approximate numbers if known:

ightharpoonup NHS organisations in England 65 2

NHS organisations in Wales

215928/1011412/37/342 Date: 23/09/2016 23

IRAS Form IRAS Version 5.3.2 Reference: 16/LO/1827 NHS organisations in Scotland 2 HSC organisations in Northern Ireland 1 GP practices in England GP practices in Wales GP practices in Scotland GP practices in Northern Ireland Joint health and social care agencies (eg community mental health teams) □ Local authorities Phase 1 trial units Prison establishments Probation areas

A73-1. Will	potential participants be identified through any organisations other than the research sites listed above?
Yes	No No

70

A74. What arrangements are in place for monitoring and auditing the conduct of the research?

The Chief Investigator will be responsible for the day to day monitoring and management of the study. The /UCL/ Joint Research Office, on behalf of UCL or as Sponsor, will monitor and conduct random audits on a selection of studies in its clinical research portfolio. Monitoring and auditing will be conducted in accordance with the Department of Health Research Governance Framework for Health & Social Care (April, 2005), and in accordance with the Sponsor's monitoring and audit policies and procedures.

The study project team are meeting monthly and reviews all aspects of the conduct of the research.

The study steering group meets quarterly and provides guidance on the study overall.

The study project team reports monthly to the Board of the National Institute for Academic Anaesthesia's Health.

Services Research Centre (NIAA-HSRC) based at the Royal College of Anaesthetists

All project team minutes are reviewed by the NIAA-HSRC monthly and the steering group quarterly.

The steering group minutes are reviewed by the NIAA-HSRC monthly.

An annual report will be provided to the R&D office at UCLH.

Independent (private or voluntary sector)

☐ Educational establishments ☐ Independent research units

Other (give details)

Total UK sites in study:

organisations

A76. Insurance/ indemnity to meet potential legal liabilities

<u>Note:</u> in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social Care (HSC) in Northern Ireland

A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.

Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes.

IRAS Form Reference: IRAS Version 5.3.2

Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.

□ NHS indemnity scheme will apply (NHS sponsors only)

☑ Other insurance or indemnity arrangements will apply (give details below)

The management of the research will be covered by UCL insurance for negligent harm

Please enclose a copy of relevant documents.

A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as applicable.

<u>Note:</u> Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors (e.g. company employees, university members), please describe the arrangements and provide evidence.

 $\ensuremath{\overline{\mathbf{W}}}$ NHS indemnity scheme will apply (protocol authors with NHS contracts only)

Other insurance or indemnity arrangements will apply (give details below)

The protocol author is an NHS employee (SR Moonesinghe)

Please enclose a copy of relevant documents.

A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of investigators/collaborators arising from harm to participants in the <u>conduct</u> of the research?

<u>Note:</u> Where the participants are NHS patients, indemnity is provided through the NHS schemes or through professional indemnity. Indicate if this applies to the whole study (there is no need to provide documentary evidence). Where non-NHS sites are to be included in the research, including private practices, please describe the arrangements which will be made at these sites and provide evidence.

NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only)

Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites below)

Please enclose a copy of relevant documents.

A78. Could the research lead to the development of a new product/process or the generation of intellectual property?

○ Yes ● No ○ Not sure

PART C: Overview of research sites

Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for the research sites. For NHS sites, the host organisation is the Trust or Health Board. Where the research site is a primary care site, e.g. GP practice, please insert the host organisation (PCT or Health Board) in the Institution row and insert the research site (e.g. GP practice) in the Department row.

Investigator identifier	Research site		Investigator Nam	ne
IN1	NHS site		_	
	O Non-NHS s	ite	Forename Middle name	Adrienne
	Country: Engla	ınd	Family name Email Qualification (MD)	Stewart adrienne.stewart@uclh.nhs.uk FRCA
	Organisation name	UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	250 EUSTON ROAD		
		LONDON GREATER LONDON		
	Post Code	NW1 2PG		
IN2	NHS siteNon-NHS s	ite	Forename Middle name	Mark
				Edwards
			Family name Email	Edwards m.edwards@soton.ac.uk
	Country: Engla		Family name	
			Family name Email Qualification	m.edwards@soton.ac.uk
	Country: Engla Organisation	SOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST MAILPOINT 18	Family name Email Qualification (MD)	m.edwards@soton.ac.uk FRCA
	Country: Engla Organisation name	SOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST	Family name Email Qualification (MD)	m.edwards@soton.ac.uk FRCA
	Country: Engla Organisation name	SOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST MAILPOINT 18 SOUTHAMPTON GENERAL	Family name Email Qualification (MD)	m.edwards@soton.ac.uk FRCA

IN3	NHS site			
	Non-NHS si	ite	Forename	David
	0 14011-14110 3	nc .	Middle name	
			Family name	Saunders
	Country: Engla	nd	Email	david.saunders@nuth.nhs.uk
			Qualification (MD)	FRCA
	Organisation name	THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	FREEMAN HOSPITAL		
		FREEMAN ROAD		
		HIGH HEATON NEWCASTLE-UPON-TYNE TYNE AND WEAR		
	Post Code	NE7 7DN		
IN4	O NILIO . II			
	NHS site		Forename	Tim
	Non-NHS s	ite	Middle name	
			Family name	Cook
	Country: Engla	nd	Email Qualification (MD)	timcook007@gmail.com
	Journal, Lingua			FRCA
	Organisation name Address	ROYAL UNITED HOSPITAL BATH NHS TRUST COMBE PARK	Country	UNITED KINGDOM
	Doot Code	BATH AVON		
	Post Code	BA1 3NG		
IN5	NHS site			
	Non-NHS s	ite	Forename Middle name	Gary
			Family name	Minto
	Country: Engla	nd	Email	gary.minto@nhs.net
			Qualification (MD)	FRCA
	Organisation name	PLYMOUTH HOSPITALS NHS TRUST	Country	UNITED KINGDOM
	Address	DERRIFORD HOSPITAL DERRIFORD ROAD PLYMOUTH DEVON		
	Post Code	PL6 8DH		

IN6	O NII 10 - 14 -			
	NHS siteNon-NHS si	te	Forename Middle name Family name	Vishal Patil
	Country: Engla	nd	Email Qualification (MD)	vishal.patil@addenbrookes.nhs.uk FRCA
	Organisation name	CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	ADDENBROOKES HOSPITAL HILLS ROAD CAMBRIDGE		
	Post Code	CAMBRIDGESHIRE CB2 0QQ		
IN7	NHS site		F	D
	Non-NHS si	te	Forename Middle name Family name	Moloney 500 C
	Country: England		Email Qualification (MD)	dmoloney586@googlemail.com
	Organisation name	AINTREE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	UNIVERSITY HOSPITAL AINTREE FAZAKERLEY HOSPITAL		
	Post Code	LOWER LANE LIVERPOOL MERSEYSIDE L9 7AL		
IN8	NHS site			
	◯ Non-NHS si	te	Forename Middle name Family name	Inese Kutovaja
	Country: Engla	nd	Email Qualification (MD)	Inese.kutovaja@boltonft.nhs.uk
	Organisation name	ROYAL BOLTON HOSPITAL NHS FOUNDATION TRUST THE ROYAL BOLTON	Country	UNITED KINGDOM
	Address	HOSPITAL MINERVA ROAD		

	Dect On L	FARNWORTH BOLTON LANCASHIRE		
	Post Code	BL4 0JR		
IN9	NHS site		_	
	Non-NHS s	ite	Forename Middle name	Andrew
			Family name	Brennan
	Country: Engla	nd	Email	Andrew.Brennan@bthft.nhs.uk
			Qualification (MD)	FRCA
	Organisation name	BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	BRADFORD ROYAL INFIRMARY		
		DUCKWORTH LANE		
		BRADFORD WEST YORKSHIRE		
	Post Code	BD9 6RJ		
IN10	NHS site			
	O Non-NHS s	ite	Forename Middle name	Mark
			Family name	Paul
	Country: Engla	nd	Email Qualification (MD)	Mark.Paul@bsuh.nhs.uk FRCA
	Organisation name	BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS TRUST	Country	UNITED KINGDOM
	Address	ROYAL SUSSEX COUNTY HOSPITAL		
		EASTERN ROAD		
	Post Code	BRIGHTON EAST SUSSEX BN2 5BE		
IN11	NHS site		_	
		ite	Forename	Alistair
	Non-NHS s		Middle name	
			Family name Email	Hughes alistairhughes@nhs.net
	Non-NHS s Country: Engla		Family name	Hughes alistairhughes@nhs.net FRCA

SERVICES NHS TRUST name Address **BROOMFIELD HOSPITAL COURT ROAD** CHELMSFORD ESSEX Post Code CM17ET IN12 NHS site Forename Jeremy Non-NHS site Middle name Family name Drake Email synapriori@doctors.org.uk Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM** Organisation BUCKINGHAMSHIRE name HEALTHCARE NHS TRUST Address AMERSHAM HOSPITAL WHIELDEN STREET **AMERSHAM** BUCKINGHAMSHIRE Post Code HP7 0JD **IN13** NHS site Forename Amr Non-NHS site Middle name Family name Mahdy Email a.mahdy@nhs.net Country: Scotland Qualification **FRCA** (MD...) **UNITED KINGDOM** Country Institution name NHS Grampian Department name Aberdeen Royal Infirmary Street address 2 Eday Rd Town/city Aberdeen Post Code **AB15 6RE** IN14 NHS site Forename Swati Non-NHS site Middle name Family name Karmarkar Email Swati.Karmarkar@cmft.nhs.uk Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM CENTRAL MANCHESTER** Organisation UNIVERSITY HOSPITALS name NHS FOUNDATION TRUST TRUST HEADQUARTERS, Address

COBBETT HOUSE

IRAS Version 5.3.2

MANCHESTER ROYAL **INFIRMARY** OXFORD ROAD MANCHESTER GREATER **MANCHESTER** Post Code M13 9WL IN15 NHS site Forename Jim Non-NHS site Middle name Family name Poncia Email James.Poncia@imperial.nhs.uk Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country Organisation **IMPERIAL COLLEGE** name HEALTHCARE NHS TRUST Address ST. MARYS HOSPITAL PRAED STREET **LONDON GREATER** LONDON Post Code **W2 1NY IN16** NHS site Forename David Non-NHS site Middle name Family name Windsor Email David.Windsor@glos.nhs.uk Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country **GLOUCESTERSHIRE** Organisation **HOSPITALS NHS** name FOUNDATION TRUST Address TRUST HQ 1 COLLEGE LAWN **CHELTENHAM GLOUCESTERSHIRE** Post Code GL53 7AG IN17 NHS site Forename Amir Non-NHS site Middle name Rafi Family name Email amir.rafi@nhs.net Country: England Qualification **FRCA** (MD...)

Country UNITED KINGDOM **COUNTY DURHAM AND** Organisation DARLINGTON NHS name FOUNDATION TRUST DARLINGTON MEMORIAL Address **HOSPITAL** HOLLYHURST ROAD DARLINGTON COUNTY **DURHAM** Post Code DL3 6HX **IN18** NHS site Forename Susie Non-NHS site Middle name Family name Baker Email Susie.baker@dchft.nhs.uk Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM** DORSET COUNTY Organisation **HOSPITAL NHS** name FOUNDATION TRUST DORSET COUNTY Address **HOSPITAL** WILLIAMS AVENUE DORCHESTER DORSET Post Code DT1 2JY **IN19** NHS site Julian Forename Non-NHS site Middle name Family name Sonksen Email Julian.Sonksen@dgh.nhs.uk Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country THE DUDLEY GROUP OF Organisation HOSPITALS NHS name FOUNDATION TRUST Address C BLOCK RUSSELLS HALL HOSPITAL PENSNETT ROAD DUDLEY WEST MIDLANDS Post Code DY1 2HQ **IN20** NHS site Forename Srikanth Non-NHS site Middle name

	Country: Engla Organisation name Address Post Code	EAST LANCASHIRE HOSPITALS NHS TRUST ROYAL BLACKBURN HOSPITAL HASLINGDEN ROAD BLACKBURN LANCASHIRE BB2 3HH	Family name Email Qualification (MD) Country	Chukkambotla Srikanth.Chukkambotla@elht.nhs.uk FRCA UNITED KINGDOM
IN21	NHS site Non-NHS s	ite	Forename Middle name Family name	Simon
	Country: Engla Organisation name	nd EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST	Email Qualification (MD) Country	simon.rang@nhs.net FRCA UNITED KINGDOM
	Address Post Code	KENT & CANTERBURY HOSPITAL ETHELBERT ROAD CANTERBURY KENT CT1 3NG		
IN22	NHS site Non-NHS s		Forename Middle name	Zoe
	Country: Engla	nd	Family name Email Qualification (MD)	Ridgway Zoe.Ridgway@gwh.nhs.uk FRCA
	Organisation name	GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	GREAT WESTERN HOSPITAL MARLBOROUGH ROAD SWINDON WILTSHIRE		
	Post Code	SN3 6BB		

IN	23				I
		IHS site		Forename	Fang
	○ I	Ion-NHS site	9	Middle name	. a.i.g
				Family name	Gao Smith
	Coun	Country: England			F.GaoSmith@bham.ac.uk
	Coun	ay. Englan	.	Qualification (MD)	FRCA
		nisation	HEART OF ENGLAND NHS	Country	UNITED KINGDOM
	name Addre		FOUNDATION TRUST BIRMINGHAM HEARTLANDS HOSPITAL		
			BORDESLEY GREEN EAST		
			BIRMINGHAM WEST MIDLANDS		
	Post (Code	B9 5ST		
IN	24	IHS site			
	0	lon-NHS site	9	Forename	Tabitha
	Ü			Middle name	_
				Family name	Tanqueray
	Coun	try: Englan	d	Email Qualification (MD)	Tabitha.Tanqueray@homerton.nhs.uk FRCA
					UNITED KINGDOM
	Orgar name	nisation	HOMERTON UNIVERSITY HOSPITAL NHS FOUNDATION TRUST	Country	ONTEDIMINODOM
	Addre	ess	HOMERTON ROW		
			LONDON GREATER LONDON		
	Post (Code	E9 6SR		
IN	25	IHS site			
	0	Ion-NHS site	e	Forename	Tim
	0.			Middle name Family name	[]
					Hughes
	Coun	try: Englan	d	Email Qualification	t.hughes1@nhs.net
				(MD)	FRCA
	Orgar name	nisation	KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Addre	ess	DENMARK HILL		
			LONDON GREATER LONDON		
	Post (Code	SE5 9RS		

IN26	NHS site			
	Non-NHS si	te	Forename	Zara
	0.101.111.0		Middle name	
			Family name	Townley
	Country: Engla	nd	Email Qualification	Zara.Townley@LTHTR.nhs.uk FRCA
			(MD)	
	Organisation name	LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	CHIEF EXECUTIVE'S OFFICE		
		ROYAL PRESTON HOSPITAL SHAROE GREEN LANE, FULWOOD PRESTON LANCASHIRE		
	Post Code	PR2 9HT		
IN27	O NII 10 - 11 -			
	NHS site		Forename	Simon
	O Non-NHS si	te	Middle name	
			Family name	Howell
	Country: Engla	nd	Email	s.howell@leeds.ac.uk
			Qualification (MD)	FRCA
	Organization	LEEDS TEACHING	Country	UNITED KINGDOM
	Organisation name	LEEDS TEACHING HOSPITALS NHS TRUST		
	Address	ST. JAMES'S UNIVERSITY HOSPITAL		
		BECKETT STREET		
	Post Code	LEEDS WEST YORKSHIRE LS9 7TF		
	Post Code	L59 / IF		
IN28	NHS site			
	O Non-NHS si	te	Forename	Jamie
	J		Middle name	Gross
			Family name Email	Gross j.gross@nhs.net
	Country: Engla	nd	Qualification (MD)	FRCA
	Organisation	NORTH WEST LONDON	Country	UNITED KINGDOM
	name	HOSPITALS NHS TRUST NORTHWICK PARK		
	Address	HOSPITAL		
		WATFORD ROAD		

IRAS Form

Reference: IRAS Version 5.3.2 16/LO/1827 HARROW MIDDLESEX Post Code HA13UJ **IN29** NHS site Graziana Forename Non-NHS site Middle name Family Massolini Country: England name Graziana.Massolini@mkhospital.nhs.uk Email Qualification FRCA (MD...) Organisation MILTON KEYNES HOSPITAL name NHS FOUNDATION TRUST **UNITED KINGDOM** Country Address STANDING WAY **EAGLESTONE** MILTON KEYNES BUCKINGHAMSHIRE Post Code MK6 5LD **IN30** NHS site Forename Richard Non-NHS site Middle name Family name Gibbs Email richardhgibbs@hotmail.com Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM** TAUNTON AND SOMERSET Organisation name NHS FOUNDATION TRUST MUSGROVE PARK Address **HOSPITAL TAUNTON SOMERSET** Post Code TA1 5DA IN31 NHS site Forename Sharon Non-NHS site Middle name Hilton-Christie Family name Email sharonchristie@nhs.net Country: Scotland Qualification **FRCA**

(MD...)

UNITED KINGDOM Country NHS Tayside Institution name

Street address Town/city Dundee

Department name Ninewells Hospital

	Post Code	DD1 9SY		
IN32	NHS site Non-NHS s Country: Engla	and	Forename Middle name Family name Email Qualification (MD) Country	Caroline Reavley caroline.reavley@btinternet.com FRCA UNITED KINGDOM
	Organisation name Address	NORFOLK AND NORWICH UNIVERSITY HOSPITALS NHS FOUNDATION TRUST COLNEY LANE COLNEY NORWICH NORFOLK		
IN33	Post Code NHS site	NR4 7UY		
	Non-NHS s		Forename Middle name Family name Email	Sarah Martindale Sarah.Martindale@nbt.nhs.uk
	Country: Engla	and	Qualification (MD)	FRCA
	Organisation name Address	NORTH BRISTOL NHS TRUST FRENCHAY HOSPITAL BECKSPOOL ROAD FRENCHAY BRISTOL AVON	Country	UNITED KINGDOM
	Post Code	BS16 1JE		
IN34	NHS site Non-NHS s	site	Forename Middle name Family name	Simon Hebard
	Country: Engla	and	Email Qualification (MD)	simon.hebard@nhs.net
	Organisation name Address	NORTHERN DEVON HEALTHCARE NHS TRUST NORTH DEVON DISTRICT HOSPITAL RALEIGH PARK BARNSTAPLE DEVON	Country	UNITED KINGDOM
	Post Code	EX31 4JB		

IN35	NHS site Non-NHS site	te	Forename Middle name Family name	Stephen
	Country: Englar	nd	Email Qualification (MD)	stephen.webb@nhs.net
	Organisation name Address Post Code	PAPWORTH HOSPITAL NHS FOUNDATION TRUST PAPWORTH EVERARD CAMBRIDGE CAMBRIDGESHIRE CB23 3RE	Country	UNITED KINGDOM
IN36	NHS site Non-NHS site	te	Forename Middle name Family name	Balraj Appadu
	Country: Englar	nd	Email Qualification (MD)	Balraj.Appadu@pbh-tr.nhs.uk
	Organisation name Address	PETERBOROUGH AND STAMFORD HOSPITALS NHS FOUNDATION TRUST EDITH CAVELL HOSPITAL BRETTON GATE BRETTON PETERBOROUGH	Country	UNITED KINGDOM
	Post Code	CAMBRIDGESHIRE PE3 9GZ		
IN37	NHS site Non-NHS site	te	Forename	Marie
	Country: Englar	nd	Middle name Family name Email Qualification (MD)	Nixon marie@duboulay.net FRCA
	Organisation name Address	PORTSMOUTH HOSPITALS NHS TRUST DE LA COURT HOUSE QUEEN ALEXANDRA HOSPITAL	Country	UNITED KINGDOM

SOUTHWICK HILL ROAD PORTSMOUTH HAMPSHIRE Post Code PO6 3LY

IN38

NHS site

Forename Brian Non-NHS site

Middle name

Family name McCreath

Email brianmccreath@nhs.net Country: Scotland

Qualification **FRCA** (MD...)

Gent

UNITED KINGDOM Country

NHS Greater Glasgow and Institution name

Clyde

Department name Queen Elizabeth Hospital,

Glasgow

Street address 1345 Govan Rd

Town/city Glasgow Post Code G51 4TF

IN39

NHS site

Forename Emma Non-NHS site

Middle name Family name

Email emma_gent@doctors.org.uk Country: England

Qualification **FRCA**

(MD...) Country **UNITED KINGDOM**

THE QUEEN ELIZABETH Organisation HOSPITAL, KING'S LYNN. name

NHS FOUNDATION TRUST QUEEN ELIZABETH

Address **HOSPITAL**

GAYTON ROAD

KINGS LYNN NORFOLK

HOSPITAL

Post Code **PE30 4ET**

IN40

NHS site Forename

Andy Non-NHS site Middle name

Bracewell Family name

Email andrew.bracewell@ghnt.nhs.uk Country: England

Qualification **FRCA** (MD...)

Country **UNITED KINGDOM**

Organisation **GATESHEAD HEALTH NHS** name FOUNDATION TRUST

QUEEN ELIZABETH Address

	Post Code	GATESHEAD TYNE AND WEAR NE9 6SX		
IN41	NHS site Non-NHS si Country: Scotla Institution name Department nam Street address Town/city Post Code	nd	Forename Middle name Family name Email Qualification (MD) Country	Dev Srivastava dev.srivastava@nhs.net FRCA UNITED KINGDOM
IN42	NHS siteNon-NHS siteNon-NHS siteCountry: EnglaOrganisation nameAddressPost Code		Middle name Family Re name Email Je Qualification (MD)	nnie echner nnie.Rechner@royalberkshire.nhs.uk RCA INITED KINGDOM
IN43	NHS site Non-NHS si Country: Engla Organisation name Address		Forename Middle name Family name Email Qualification (MD) Country	James Craig James.Craig@rbch.nhs.uk FRCA UNITED KINGDOM

Reference: 16/LO/1827 **IRAS Form** IRAS Version 5.3.2

	Post Code	BOURNEMOUTH DORSET BH7 7DW		
IN44	NHS site Non-NHS s	ite	Forename Middle name	Kath
	Country: Engla	and	Family name Email Qualification (MD)	Meikle katharine.meikle@nhs.net FRCA
	Organisation name	ROYAL DEVON AND EXETER NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	ROYAL DEVON & EXETER HOSPITAL BARRACK ROAD EXETER DEVON		
	Post Code	EX2 5DW		
IN45	NHS site			
	Non-NHS s	ite	Forename Middle name	Dan Martin
	Country: Engla	ind	Family name Email	Martin daniel.martin@ucl.ac.uk
	J		Qualification (MD)	FRCA
	Organisation name	ROYAL FREE HAMPSTEAD NHS TRUST	Country	UNITED KINGDOM
	Address	ROYAL FREE HOSPITAL POND STREET LONDON GREATER LONDON		
	Post Code	NW3 2QG		
IN46	NHS site			
	Non-NHS s	ite	Forename Middle name	Matt
	Country: Engla	and	Family name Email Qualification (MD)	Wikner wiknermatt@yahoo.co.uk FRCA
	Organisation name	BARTS AND THE LONDON NHS TRUST	Country	UNITED KINGDOM
	Address	TRUST OFFICES, WHITECHAPEL		

THE ROYAL LONDON **HOSPITAL** WHITECHAPEL LONDON **GREATER LONDON** Post Code E1 1BB **IN47** NHS site Forename Susanna Non-NHS site Middle name Family name Walker Email susannawalker@yahoo.co.uk Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country Organisation THE ROYAL MARSDEN NHS name **FOUNDATION TRUST** Address **FULHAM ROAD LONDON GREATER** LONDON Post Code SW3 6JJ **IN48** NHS site Forename Oliver Non-NHS site Middle name Family name Pratt Email Oliver.Pratt@srft.nhs.uk Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country Organisation SALFORD ROYAL NHS name FOUNDATION TRUST Address SALFORD ROYAL STOTT LANE SALFORD GREATER MANCHESTER M6 8HD Post Code IN49 NHS site Forename Subash Non-NHS site Middle name Family name Sivasubramaniam Email s.sivasubramaniam@nhs.net Country: England Qualification **FRCA**

(MD...)

Country UNITED KINGDOM SANDWELL AND WEST Organisation **BIRMINGHAM HOSPITALS** name NHS TRUST Address CITY HOSPITAL **DUDLEY ROAD BIRMINGHAM WEST MIDLANDS** Post Code B18 7QH **IN50** NHS site Forename lan Non-NHS site Middle name Family name Wrench lan.Wrench@sth.nhs.uk Email Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM** SHEFFIELD TEACHING Organisation **HOSPITALS NHS** name **FOUNDATION TRUST** NORTHERN GENERAL Address **HOSPITAL** HERRIES ROAD SHEFFIELD SOUTH YORKSHIRE Post Code **S5 7AU** IN51 NHS site Forename Mohan Non-NHS site Middle name Family name Ranganathan Email drmohan2k@hotmail.com Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country Organisation SOUTH WARWICKSHIRE name NHS FOUNDATION TRUST Address WARWICK HOSPITAL LAKIN ROAD WARWICK WARWICKSHIRE Post Code CV34 5BW **IN52** NHS site Forename **Bobby** Non-NHS site Middle name Family name Krishnachetty

Bobby.Krishnachetty@southend.nhs.uk Email Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM** SOUTHEND UNIVERSITY Organisation HOSPITAL NHS name FOUNDATION TRUST Address PRITTLEWELL CHASE WESTCLIFF ON SEA ESSEX Post Code SS0 0RY **IN53** NHS site Forename Guy Non-NHS site Middle name Sanders Family name Email guysanders@doctors.org.uk Country: England Qualification **FRCA** (MD...) **UNITED KINGDOM** Country ST GEORGE'S Organisation HEALTHCARE NHS TRUST name Address ST GEORGE'S HOSPITAL **BLACKSHAW ROAD TOOTING LONDON GREATER LONDON** Post Code **SW17 0QT** IN54 NHS site Forename James Non-NHS site Middle name Family name Tulloch Email james.tulloch@chsft.nhs.uk Country: England Qualification **FRCA** (MD...) Country **UNITED KINGDOM** CITY HOSPITALS Organisation SUNDERLAND NHS name FOUNDATION TRUST SUNDERLAND ROYAL Address **HOSPITAL** KAYLL ROAD SUNDERLAND TYNE AND **WEAR** Post Code SR4 7TP

IN55	NHS site			
	Non-NHS site Country: England		Forename Middle name Family name	Dave Murray
			Email Qualification (MD)	dave.murray@stees.nhs.uk
	Organisation name	SOUTH TEES HOSPITALS NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	JAMES COOK UNIVERSITY HOSPITAL		
		MARTON ROAD MIDDLESBROUGH CLEVELAND		
	Post Code	TS4 3BW		
IN56	O NII 10 -: t-			
	NHS siteNon-NHS s	ite	Forename Middle name	Mike
			Family name	Swart
	Country: England		Email Qualification	michael.swart@nhs.net FRCA
			(MD) Country	UNITED KINGDOM
	Organisation name	SOUTH DEVON HEALTHCARE NHS FOUNDATION TRUST		
	Address	HENGRAVE HOUSE		
		TORBAY HOSPITAL NEWTON ROAD TORQUAY DEVON		
	Post Code	TQ2 7AA		
IN57	♠ NILIC cite			
	NHS siteNon-NHS s	ite	Forename	Mathew
			Middle name Family name	Patteril
	Country: Engla	and	Email Qualification (MD)	Mathew.Patteril@uhcw.nhs.uk FRCA
		UNIVERSITY HOSPITALS COVENTRY AND	Country	UNITED KINGDOM
	Organisation name	WARWICKSHIRE NHS TRUST		

	Post Code	COVENTRY WEST MIDLANDS CV2 2DX		
IN59	NHS site			
	Non-NHS s	ite	Forename Middle name	Claire
			Family name	
	Country: Engla	nd	Email	Claire.Dowse@UHBristol.nhs.uk
			Qualification (MD)	FRCA
	Organisation name	UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	MARLBOROUGH STREET		
	Post Code	BRISTOL AVON BS1 3NU		
IN60	NHS site		Forename	Deve
	Non-NHS s	○ Non-NHS site		Prea e
			Family name	
	Country: Engla	nd	Email Qualification (MD)	prea.ramasamy@uhl-tr.nhs.uk FRCA
	Organisation name	UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST	Country	UNITED KINGDOM
	Address	GWENDOLEN HOUSE		
		GWENDOLEN ROAD LEICESTER LEICESTERSHIRE		
	Post Code	LE5 4QF		
IN61	NHS site			
	Non-NHS si	ite	Forename Middle name	Matthew
	Country: Scotla	and	Family name	Royds
			Email	Matthew.Royds@nhslothian.scot.nhs.uk
	Institution name	NHS Lothian	Qualification (MD)	FRCA
		ne Western General Hospital Crewe Rd S	Country	UNITED KINGDOM

IRAS Form

IRAS Version 5.3.2

	Town/city Post Code	Edinburgh EH4 2XU		
IN62	NHS site Non-NHS si	te	Forename Middle name	Jane
	Country: Engla	nd	Family name Email Qualification (MD)	Silk jane.silk@nhs.net FRCA
	Organisation name Address	THE WHITTINGTON HOSPITAL NHS TRUST THE WHITTINGTON HOSPITAL MAGDALA AVENUE LONDON GREATER	Country	UNITED KINGDOM
	Post Code	LONDON N19 5NF		
IN63	NHS site Non-NHS si	te	Forename Middle name Family name	Kathryn Brodbelt
	Country: Engla	nd	Email Qualification (MD)	kathrynbrodbelt@nhs.net FRCA
	Organisation name Address	WIRRAL UNIVERSITY TEACHING HOSPITAL NHS FOUNDATION TRUST ARROWE PARK HOSPITAL ARROWE PARK ROAD UPTON WIRRAL	Country	UNITED KINGDOM
	Post Code	MERSEYSIDE CH49 5PE		
IN64	NHS site Non-NHS si	te	Forename Middle name Family name	Agniezsa Kubisz-Pudelko
	Country: Engla	nd	Email Qualification (MD)	agnieszka.kubisz- pudelko@ydh.nhs.uk FRCA
	Organisation name Address	YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST YEOVIL DISTRICT HOSPITAL HIGHER KINGSTON YEOVIL SOMERSET	Country	UNITED KINGDOM

•				
	Post Code	BA21 4AT		
IN65	NHS site			
	Non-NHS si	te	Forename	Jonathan
			Middle name Family name Email	Wilson Jonathan.RJT.Wilson@York.NHS.UK
	Country: Englar	nd	Qualification (MD)	FRCA
	Organisation name	YORK TEACHING HOSPITAL NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	YORK HOSPITAL WIGGINTON ROAD YORK NORTH YORKSHIRE		
	Post Code	YO31 8HE		
IN66	NHS site			
			Forename	Matt
	Non-NHS si	le	Middle name	
			Family name	Dickinson
	Country: Englar	nd	Email	matthew.dickinson@gmail.com
	commy. Ingres		Qualification (MD)	FRCA
	Organisation name	ROYAL SURREY COUNTY HOSPITAL NHS FOUNDATION TRUST	Country	UNITED KINGDOM
	Address	EGERTON ROAD		
		GUILDFORD SURREY		
	Post Code	GU2 7XX		
IN67	NHS site			
	Non-NHS si	te	Forename	Vincent
	0		Middle name	Harri a
			Family name Email	Hamlyn
	Country: Wales		Qualification (MD)	vincent.hamlyn@doctors.org.uk FRCA
	Institution name	Aneurin Bevan University Healthboard	Country	UNITED KINGDOM
	Department nam	e Nevill Hall Hospital		
	Street address	Brecon Road		
	Town/city	Abergavenny		
	Post Code	NP7 7EG		

IN68	NHS site			
	Non-NHS sit	e	Forename Middle name	Clare
			Family name	Kelly
	Country: Northern Ireland		Email	Clare.Kelly@belfasttrust.hscni.ne
	odunay. Horase	woland	Qualification (MD)	FRCA
	Institution name	Belfast Health and Social Care Trust	Country	UNITED KINGDOM
	Department name	e Belfast City Hospital		
	Street address	Lisburn Road		
	Town/city	Belfast		
	Post Code	BT9 7AB		

PART D: Declarations

D1. Declaration by Chief Investigator

- 1. The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
- 2. I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice guidelines on the proper conduct of research.
- 3. If the research is approved I undertake to adhere to the study protocol, the terms of the full application as approved and any conditions set out by review bodies in giving approval.
- 4. I undertake to notify review bodies of substantial amendments to the protocol or the terms of the approved application, and to seek a favourable opinion from the main REC before implementing the amendment.
- 5. I undertake to submit annual progress reports setting out the progress of the research, as required by review bodies.
- 6. I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines relating to security and confidentiality of patient or other personal data, including the need to register when necessary with the appropriate Data Protection Officer. I understand that I am not permitted to disclose identifiable data to third parties unless the disclosure has the consent of the data subject or, in the case of patient data in England and Wales, the disclosure is covered by the terms of an approval under Section 251 of the NHS Act 2006.
- 7. I understand that research records/data may be subject to inspection by review bodies for audit purposes if required.
- 8. I understand that any personal data in this application will be held by review bodies and their operational managers and that this will be managed according to the principles established in the Data Protection Act 1998.
- 9. I understand that the information contained in this application, any supporting documentation and all correspondence with review bodies or their operational managers relating to the application:
 - Will be held by the REC (where applicable) until at least 3 years after the end of the study; and by NHS R&D offices (where the research requires NHS management permission) in accordance with the NHS Code of Practice on Records Management.
 - May be disclosed to the operational managers of review bodies, or the appointing authority for the REC (where applicable), in order to check that the application has been processed correctly or to investigate any complaint.
 - May be seen by auditors appointed to undertake accreditation of RECs (where applicable).
 - Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response to requests made under the Acts except where statutory exemptions apply.
 - May be sent by email to REC members.
- 10. I understand that information relating to this research, including the contact details on this application, may be held on national research information systems, and that this will be managed according to the principles established in the Data Protection Act 1998.
- 11. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I understand that the summary of this study will be published on the website of the National Research Ethics Service (NRES), together with the contact point for enquiries named below. Publication will take place no earlier than 3 months after issue of the ethics committee's final opinion or the withdrawal of the application.

Contact point for publication(*Not applicable for R&D Forms*)

NRES would like to include a contact point with the published summary of the study for those wishing to seek further information. We would be grateful if you would indicate one of the contact points below.

Chief Investigator

IRAS Form Reference: IRAS Version 5.3.2 16/LO/1827

Sponsor					
Study co-ordinator					
Student					
Other – please give	details				
None					
	Access to application for training purposes (Not applicable for R&D Forms) Optional – please tick as appropriate:				
☐ I would be content for members of other RECs to have access to the information in the application in confidence for training purposes. All personal identifiers and references to sponsors, funders and research units would be removed.					
This section was signed electronically by Dr Suneetha Ramani Moonesinghe on 23/09/2016 15:56.					
Job Title/Post:	Consultant Anaesthetist				
Organisation:	UCLH				
Email:	rmoonesinghe@gmail.com				

Date: 23/09/2016 51 215928/1011412/37/342

D2. Declaration by the sponsor's representative

If there is more than one sponsor, this declaration should be signed on behalf of the co-sponsors by a representative of the lead sponsor named at A64-1.

I confirm that:

- 1. This research proposal has been discussed with the Chief Investigator and agreement in principle to sponsor the research is in place.
- 2. An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and of high scientific quality.
- Any necessary indemnity or insurance arrangements, as described in question A76, will be in place before this research starts. Insurance or indemnity policies will be renewed for the duration of the study where necessary.
- 4. Arrangements will be in place before the study starts for the research team to access resources and support to deliver the research as proposed.
- 5. Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will be in place before the research starts.
- 6. The duties of sponsors set out in the Research Governance Framework for Health and Social Care will be undertaken in relation to this research.
 - Please note: The declarations below do not form part of the application for approval above. They will not be considered by the Research Ethics Committee.
- 7. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I understand that the summary of this study will be published on the website of the National Research Ethics Service (NRES), together with the contact point for enquiries named in this application. Publication will take place no earlier than 3 months after issue of the ethics committee's final opinion or the withdrawal of the application.
- 8. Specifically, for submissions to the Research Ethics Committees (RECs) I declare that any and all clinical trials approved by the HRA since 30th September 2013 (as defined on IRAS categories as clinical trials of medicines, devices, combination of medicines and devices or other clinical trials) have been registered on a publically accessible register in compliance with the HRA registration requirements for the UK, or that any deferral granted by the HRA still applies.

This section was signed electronically by Miss Tabitha Kavoi on 23/09/2016 16:54.

Job Title/Post: Research Management and Governance Manager

Organisation: University College London

Email: randd@uclh.nhs.uk